MMMohammad Minakari

Mohammad Minakari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mohammad Minakari has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Success Rate of Endoscopic Treatment for Post-Sleeve Gastrectomy Leaks: A Systematic Review and Meta-Analysis

    by Mohammad Minakari, Vahid Sebghatollahi, Majid Namaki

    Background Sleeve gastrectomy (SG) is effective for obesity treatment but can lead to complications like postoperative leaks and fistulas. Endoscopic interventions have become the preferred method of management due to their minimally invasive nature. This meta-analysis evaluates the success rates and complications of various endoscopic treatments for leaks post-SG. Methods A systematic review and meta-analysis following PRISMA 2020 guidelines included 58 studies with 18,685 patients. The databases searched included Scopus, Embase, PubMed, Google Scholar, Web of Science, and Cochrane from inception until February 2025 using related keywords based on search strategy. Data on demographics, intervention types, success rates, and complications were analyzed using R software. Results Among 18,685 patients, 2896 developed postoperative leaks. The overall success rate of endoscopic interventions was 88% (95% CI: 85–91.1%; p < 0.0001). Stenting was the most common intervention (48.02%) with a success rate of 90.6% (95% CI: 87.7–93.6%). Endoscopic suturing had the highest success rate (91%; 95% CI: 78.2–100%), followed by endoscopic vacuum therapy (85.1%; 95% CI: 69.4–100%), internal drainage (84.5%; 95% CI: 81.6–87.6%), and over-the-scope clips (77.1%; 95% CI: 55.9–98.2%). The most common complications were stent migration (24.5%) and stenosis (5%). Sensitivity analyses confirmed robust results with no significant publication bias (p = 0.6335). Conclusion Endoscopic interventions are effective for managing postoperative leaks after sleeve gastrectomy. Stenting and suturing have the highest success rates, though complications like stent migration require attention.


  • Comparison of the Bile Reflux Frequency in One Anastomosis Gastric Bypass and Roux-en-Y Gastric Bypass: a Cohort Study

    by Behrouz Keleidari, Mohsen Mahmoudieh, Amir Hosein Davarpanah Jazi, Hamid Melali, Farid Nasr Esfahani, Mohammad Minakari, Mojgan Mokhtari

    One of the most acceptable procedures in bariatric surgery is laparoscopic gastric bypass. Laparoscopic Roux-en-Y gastric bypass (RYGB) is a common technique used in bariatric surgery. Recently, one anastomosis gastric bypass (OAGB) has been suggested as a simple, fast, and effective technique for obesity treatment. This study aims to compare the frequency of histologically proven bile reflux in OAGB and RYGB among patients with morbid obesity.


  • Novel Variants and Copy Number Variation in CDH1 Gene in Iranian Patients with Sporadic Diffuse Gastric Cancer

    by Abbas Moridnia, Mohammad Amin Tabatabaiefar, Mehrdad Zeinalian, Mohammad Minakari, Majid Kheirollahi, Noushin Afshar Moghaddam

    The aim of this study was to survey the nucleotide changes and copy number variations (CNV) in the CDH1 gene in Iranian patients with sporadic diffuse gastric cancer (SDGC).


  • Etiology and outcome in patients with upper gastrointestinal bleeding: Study on 4747 patients in the central region of Iran

    by Mohammad Minakari, Shervin Badihian, Pooyan Jalalpour, Vahid Sebghatollahi

    Background and Aim: Upper gastrointestinal bleeding (UGIB) is a threatening condition leading to urgent hospitalization. This study aims to investigate etiology and outcome in UGIB patients in Iran.Methods: Medical records of GIB patients admitted to Alzahra referral hospital (in Isfahan) during 2010–2015 were retrospectively reviewed for demographic data, comorbidities, history of smoking and taking non‐steroidal anti‐inflammatory drugs (NSAIDs), presenting symptoms, endoscopic findings, therapeutic endoscopy, blood products' infusion, surgical intervention, rebleeding, and mortality.Results: A total of 4747 patients were enrolled in the study (69.2% men, mean age = 55.46 ± 21.98 years). Hematemesis was the most frequent presenting symptom (63.5%). Peptic ulcer (duodenal ulcer in most cases) was seen as the main reason for UGIB (42.4%). Rebleeding (present in 16.5% of patients) was found to be more frequent in patients with older age, presenting sign of hematochezia and hypotension, history of taking NSAIDs and smoking, presence of comorbidities, history of bleeding because of UGI tract neoplasm and esophageal varices, history of needing blood products' infusion, and history of therapeutic endoscopy or surgical intervention (P < 0.005). We found that mortality (5.5% in total) was also higher in the same group of patients that were seen to have a higher tendency for rebleeding (P < 0.005).Conclusion: Peptic ulcers are the most common cause of UGIB. Comorbidities, hemodynamic instability, high‐risk endoscopic stigmata, history of smoking and taking NSAIDs, gastric and esophageal malignancies, may be important predisposing factors for rebleeding and mortality in patients with UGIB.


    • 1 August 2014
      • Vol. 19  (8) , 703-708
    Open Access

    Multistrain probiotic and lactulose in the treatment of minimal hepatic encephalopathy

    by Ahmad Shavakhi, Huriyeh Hashemi, Elham Tabesh, Zhaleh Derakhshan, Somaye Farzamnia, Shirin Meshkinfar, Sara Shavakhi, Mohammad Minakari, Ali Gholamrezaei

    Background: Some evidence has shown benefits of probiotics in the management of minimal hepatic encephalopathy (MHE). We evaluated the efficacy of a multistrain probiotic compound, alone and in combination with lactulose, in the treatment of MHE. Materials and Methods: This study has two parts. First, consecutive adult patients with MHE were randomized to receive lactulose (30-60 mL/day) + probiotic (200 million colony forming units of seven bacteria species/day) (Gp-LPr) or lactulose + placebo (GpL). In second part, a non-randomized group of patients received probiotic alone (Gp-Pr). Medication duration was for 2 weeks and patients were followed-up for another 8 weeks. Improvement in MHE status was assessed by psychometric hepatic encephalopathy score (PHES). Development of overt encephalopathy, hospitalization, and death were considered as secondary outcomes. Results: Sixty patients (80% male, mean age 38.4 +/- 9.6 years) completed the intervention. PHES significantly improved after medication in all the three groups (Gp-LPr: -3.8 +/- 3.9 to -1.6 +/- 3.0; Gp-L: -4.8 +/- 4.1 to -1.6 +/- 2.9; and Gp-Pr: -4.9 +/- 3.7 to -2.1 +/- 2.5, P < 0.001). After 8 weeks follow-up, improvement was maintained in Gp-LPr and Gp-Pr, but there was deterioration in those who did not receive probiotics (Gp-L: PHES score reversed to -4.8 +/- 4.2). Two patients (one each in Gp-L and Gp-Pr) experienced overt encephalopathy. One patient was hospitalized due to worsening of ascites (Gp-LPr) and one due to spontaneous bacterial peritonitis (Gp-L). Side effects were mild and not significantly different among the groups. Conclusion: Lactulose and probiotics are effective for the treatment of MHE; however, probiotics, but not lactulose, have long-term effects. More studies are required before suggesting probiotics for the standard treatment of MHE.


  • Premedication with sublingual or oral alprazolam in adults undergoing diagnostic upper gastrointestinal endoscopy

    by Ahmad Shavakhi, Soghry Soleiman, Ali Gholamrezaei, Mahsa Khodadoostan, Sara Shavakhi, Abdolmajid Tahery, Mohammad Minakari

    Background and study aim: Diagnostic esophagogastroduodenoscopy (EGD) is uncomfortable for most patients. We determined the efficacy of alprazolam, administered orally or sublingually, as premedication for sedation during EGD. Patients and methods: Adult EGD candidates were randomly allocated to four groups (n = 55, each group) and received alprazolam (0.5 mg) sublingually or orally, placebo sublingually or orally at 30 minutes before EGD. Main outcome measures included procedure-related anxiety and pain/discomfort (assessed using 11-point numeric scales), patient overall tolerance (assessed using a 4-point Likert scale), need for intravenous sedation, and willingness to repeat the EGD if necessary. Results: Patients experienced greater reduction in anxiety score after medication with sublingual alprazolam (mean 2.25, standard deviation [SD] 1.73) compared with sublingual placebo (mean 0.10, standard error [SE] 0.15]; P < 0.001) and oral alprazolam (0.63, SE 0.14; P < 0.001). Also, pain/discomfort scores were lower with sublingual alprazolam compared with sublingual placebo (3.29, SE 0.29 vs. 4.16, SD 1.86; P = 0.024), and with oral alprazolam compared with oral placebo (3.48, SD 1.69 vs. 5.13, SD 2.39; P < 0.001). Patient overall tolerance was better with sublingual alprazolam than with sublingual placebo (P = 0.005) or with oral alprazolam (P = 0.009). Regarding intravenous sedation, there was no difference between sublingual alprazolam and sublingual placebo (10.9 % vs. 10.9 %; P = 0.619) or between oral alprazolam and oral placebo (9.0 % vs. 12.7 %; P = 0.381). Willingness to repeat the procedure was greater with sublingual alprazolam than with sublingual placebo (50.9 % vs. 30.9 %; P = 0.026). Conclusions: Sublingual alprazolam is an effective premedication for sedation during EGD. It reduces anxiety and pain/discomfort related to EGD and increases patient tolerance and willingness to repeat the EGD if necessary. Clinical trial registration: NCT01949038 ClinicalTrials.gov


    • 1 March 2014
      • Vol. 19, S1-S4
    Open Access

    Statin efficacy in the treatment of hepatitis C genotype I

    by Ahmad Shavakhi, Mohamad Minakari, Afshin Bighamian, Sina Sadeghian, Sara Shavakhi, Naser Khamisi, Mahsa Khodadustan, Majid Talebi, Behrooz Ataei

    Lipid metabolism is one of the hepatitis C virus (HCV) life cycle steps. Statins can reduce cholesterol level and finally can decrease HCV replication. Thus, we assessed the effect of Statins in combination with standard antiviral treatment on hyperlipidemic genotype I HCV infected patients. This study was a prospective clinical trial. 40 patients were selected from those referred to educational and Therapeutic Centers of Isfahan University of Medical Sciences from 2009 to 2010 with confirmed HCV viremia. All patients received Peg-interferon-a2a and ribavirin. 20 hyperlipidemic Patients received 20 mg atorvastatin nightly for 3 months and placebo was prescribed for 20 normolipidemic HCV infected patients as a control group. Liver enzymes and complete blood count were checked monthly and thyroid stimulating hormone was checked every 3 months. We also performed quantitative HCV-ribonucleic acid (RNA) test in 12th week of therapy, at the end of treatment and 6 months after therapy for all samples. We didn’t find any significant differences in the mean of HCV-RNA numbers between statin and placebo groups in 12th week of treatment, in the end of treatment and 6 months after treatment (P > 0.05). Atorvastatin has no effect on the mean of HCV viral load when we added it to standard treatment for hepatitis C infection. Further studies are necessary to examine the possible antiviral properties of statins and their potential role as adjuncts to standard HCV therapy.


    • 1 February 2014
      • Vol. 5  (2) , 145-151
    Open Access

    Efficacy of Double Dose Recombinant Hepatitis B Vaccination in Chronic Hepatitis C Patients, Compared to Standard Dose Vaccination

    by Mohammad Minakari, Afshin Tahmasebi, Mahyar Hosseini Motlagh, Behrooz Ataei, Majid Yaran, Hamid Kalantari, Hamid Tavakkoli

    Background: Hepatitis B virus (HBV) vaccination is a well-known, safe and effective way for protection against HBV infection; however, non-responders remain susceptible to infection with HBV. This is so important in patients with any kind of chronic liver disease, especially chronic hepatitis C virus (HCV) patients in whom acute HBV infection may lead to decompensation of liver disease. Some of the studies have shown that immunogenicity of HBV vaccination is decreased in these patients. The aim of this study was to evaluate the efficacy and safety of double dose vaccination of HBV in these patients, compared with standard dose vaccination in similar patients and healthy adults. Methods: A total of 64 patients with chronic HCV infection were randomized into 2 groups of 32. Group A received standard dose HBV vaccine, at 0, 1, 6 months, whereas group B received double dose HBV vaccine. Group C consisted of 32 healthy adults who also received standard dose vaccination. At 1 month after the end of vaccination, Hepatitis B surface antibody (HBsAb) titer was checked in all participants and the results were compared. Results: There was no significant difference in age or sex among three groups. The response rate in groups B and C was 100% (all had HBsAb titer > 10 mIU/mL), while in group A, 4 patients(12.5%) were non-responders (HBsAb titer < 10 mIU/mL). The difference in response rate was statistically significant between Group A and the other two groups (P < 0.05). Conclusions: The efficacy of standard dose HBV vaccination in patients with chronic HCV infection was suboptimal. Using double dose vaccination in these patients was an effective way to increase the antibody response.


  • Open Access

    The effect of Helicobacter pylori eradication on liver enzymes in patients referring with unexplained hypertransaminasemia

    by Mohammad Minakari, Hassan Salehi, Arezoo Yaghoutkar, Elham Tabesh, Marziyeh Salehi, Leila Mirbagher

    Background: Evidence has shown an association of Helicobacter pylori infection with liver dysfunction and damage. We investigated if H. pylori eradication affects liver enzymes in patients referring with unexplained hypertransaminasemia. Materials and Methods: Patients with mild unexplained hypertransaminasemia accompanied with dyspepsia and confirmed H. pylori infection were studied. Viral, metabolic, autoimmune, and drug/toxin induced hepatitis as well as fatty liver were all ruled-out by appropriate tests. Patients received bismuth-containing quadruple-therapy for 2 weeks. Serum levels of liver enzymes (alanine transaminase (ALT) and aspartate transaminase (AST)) and successful eradication (with stool antigen test) were evaluated 4 weeks after the medication. Results: A total number of 107 patients (55 males, mean age = 35.0 ± 8.4 years) were studied. Eradication was successful in 93 patients (86.9%). Serum levels of AST (6.3 ± 19.6 IU/L, P = 0.002) and ALT (7.8 ± 24.9 IU/L, P = 0.001) were significantly decreased after eradication. Levels of AST and ALT decreased to normal range respectively in 46.6% and 45.7% of the cases who had baseline levels above the normal range. Conclusion: This study showed a decrease in liver enzymes after receiving eradication regimen of H. pylori, suggesting a role for H. pylori infection in at least some of patients with mild unexplained hypertransaminasemia. Further studies are warranted to find the underlying mechanisms by which H. pylori infection affects the liver and clinical importance of such effects.


    • 1 May 2013
      • Vol. 4  (5) , 531-537
    Open Access

    Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial

    by Ahmad Shavakhi, Mohammad Minakari, Hassan Firouzian, Raheleh Assali, Azita Hekmatdoost, Gordon Ferns

    Non-alcoholic steatohepatitis (NASH) is a clinicopathological entity that is being recognized more frequently in recent years. This study aimed to evaluate the effects of Metformin, with and without a probiotic supplement on liver aminotransferases in patients with NASH. Sixty four patients 18-75 years with NASH confirmed by biopsy and histological assessment were enrolled to study. Patients were randomized to one of the following treatments for 6 months: Group I, probiotic (Protexin two tablets per day) plus Metformin 500 mg two tablets per day (Met/Pro), or group II, Metformin 500 mg two tablets per day plus two placebo tablet (Met/P). After 6 month alanine aminotransferase (ALT), aspartate aminotransferase, and ultrasound grading of NASH were assessed. In group I, serum alanine aminotransferase (ALT: 133.7 ± 70 vs. 45.2 ± 32.5; P < 0.00), and aspartate aminotransferase activity (AST: 123.1 ± 72 vs. 44.2 ± 33.9; P < 0.001), and ultrasound grading of NASH (P < 0.001) all decreased significantly by the end of the treatment period. In group II, while serum alanine aminotransferase (ALT) was not significantly reduced (118.4 ± 67.9 vs. 112.5 ± 68.7; P < 0.064), aspartate aminotransferase activity (AST: 125.3 ± 71 vs. 113.4 ± 71; P < 0.001), and ultrasound grading of NASH did fall significantly (P < 0.01). Body mass index (BMI), fasting blood sugar (FBS), cholesterol, and triglyceride fell significantly in both groups. Probiotic combination with Metformin improves liver aminotransferases better than metformin alone in patients with NASH.